ClinicalTrials.gg
CompletedNCT00523744Updated Aug 4, 2020Results posted

Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension

A Phase 3 interventional study of Amlodipine and Olmesartan medoxomil in Hypertension, sponsored by Novartis. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-04.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
75th of 186
257 · median 180
Started
2007
with 16 others
Phase 3
69 of 187
2 open now
Registered
44th of 187
by date
Lead sponsor
40 of 187
Novartis

Among the 187 studies testing amlodipine in Hypertension, this one is the 75th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 44th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension. There was an optional study extension for eligible patients who wanted to participate that contains the triple therapy (ie, hydrochlorothiazide+ amlodipine/valsartan).

Read the detailed description

Title of study extension: An open-label, multicenter extension to evaluate the efficacy and tolerability of a 4 week therapy with hydrochlorothiazide 12.5 mg plus amlodipine 10 mg/valsartan 160 mg in hypertensive patients not adequately responding to a 4 week therapy each with the combinations of olmesartan 20 mg plus amlodipine 10 mg followed by amlodipine 10 mg/valsartan 160 mg

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension, valsartan, amlodipine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Core study:

  • Male or female patients (>=18 years)
  • Females must be either for one year, surgically sterile or using effective methods
  • Patients with essential hypertension (diastolic blood pressure >=100 mmHg and \<110 mmHg)

Inclusion Criteria for Extension:

  • Patients had to have a msSBP >= 140 mmHg and/or msDBP >= 90 mmHg at week 8 ie, end of core study.

Exclusion Criteria for Core study:

  • Severe hypertension (diastolic blood pressure >=110 mmHg or systolic blood pressure >= 180 mmHg)
  • Pregnant or nursing women
  • Treated hypertensive patients with controlled hypertension under current therapy
  • A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, , stroke, and heart failure II - IV

Exclusion Criteria for Extension:

  • prematurely discontinued the core study
  • failed to comply with the core study protocol

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ

    During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.

    Drug: Amlodipine · Drug: Olmesartan medoxomil · Drug: Amlodipine+valsartan · Drug: Hydrochlorothiazide

Interventions

  • Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.

  • Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.

  • DrugAmlodipine+valsartan

    Drug pages: Amlodipine · Valsartan

    Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.

    Also known as: Exforge

  • Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.

    Also known as: Sandoz

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

    Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

  2. Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

    Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

    Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

  2. Change in Sitting Pulse Pressure During the Core Phase of the Study

    Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

    Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

  3. Change in Sitting Pulse Rate During the Core Phase of the Study

    Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.

    Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

  4. Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study

    Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.

    Time frame: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

  5. Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study

    Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 (Week 8) compared to Baseline in Phase 2 (week 4) or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.

    Time frame: Baseline of Phase 2 (Week 4) to end of Phase 2 (Week 8)

  6. Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study

    The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

    Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)

  7. Change in Sitting Pulse Pressure During the Extension Phase of the Study

    Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

    Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)

  8. Change in Sitting Pulse Rate During the Extension Phase of the Study

    Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.

    Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (week 12)

  9. Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study

    Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.

    Time frame: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)

  10. Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study

    Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 3 compared to Baseline in Phase 3 or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 3 compared to Baseline in Phase 3.

    Time frame: Baseline of Phase 3 (Week 8) to end of Phase 3 (Week 12)

07

Results

Posted May 25, 2011

Participant flow

Phase 1 - Amlodipine+Olmesartan
Participant flow — Phase 1 - Amlodipine+Olmesartan
MilestoneAmlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ
Started257
Completed251
Not completed6
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up2
Withdrew: Administrative problems1
Phase 2 - Amlodipine+Valsartan
Participant flow — Phase 2 - Amlodipine+Valsartan
MilestoneAmlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ
Started176
Completed173
Not completed3
Withdrew: Adverse event2
Withdrew: Lost to follow-up1
Phase 3 - Amlodipine+Valsartan+HCTZ
Participant flow — Phase 3 - Amlodipine+Valsartan+HCTZ
MilestoneAmlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ
Started91
Completed91
Not completed0

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

Time frame:
Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
mmHgAmlodipine+Valsartan - Phase 2
Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study-9.13 ± 1.97
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

Time frame:
Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Reported as:
Mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
mmHgAmlodipine+Valsartan - Phase 2
Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study-7.87 ± 9.48
SecondaryChange in Sitting Pulse Pressure During the Core Phase of the Study

Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

Time frame:
Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Reported as:
Mean · mmHg
Change in Sitting Pulse Pressure During the Core Phase of the Study
mmHgAmlodipine+Valsartan - Phase 2
Change in Sitting Pulse Pressure During the Core Phase of the Study1.26 ± 9.64
SecondaryChange in Sitting Pulse Rate During the Core Phase of the Study

Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.

Time frame:
Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Reported as:
Mean · BPM (beats per minute)
Change in Sitting Pulse Rate During the Core Phase of the Study
BPM (beats per minute)Amlodipine+Valsartan - Phase 2
Change in Sitting Pulse Rate During the Core Phase of the Study-1.93 (-3.06 to -0.79)
PrimaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

Time frame:
Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
mmHgAmlodipine+Valsartan+HCTZ - Phase 3
Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study-5.22 (-6.76 to -3.68)
SecondaryPercentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study

Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.

Time frame:
Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
Percentage of participantsAmlodipine+Valsartan - Phase 2
msSBP < 140 mmHg44.6
msDBP < 90 mmHg72.6
SecondaryPercentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study

Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 (Week 8) compared to Baseline in Phase 2 (week 4) or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.

Time frame:
Baseline of Phase 2 (Week 4) to end of Phase 2 (Week 8)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
Percentage of participantsAmlodipine+Valsartan - Phase 2
msSBP response47.4
msDBP response73.1
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

Time frame:
Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Reported as:
Mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
mmHgAmlodipine+Valsartan+HCTZ - Phase 3
Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study-10.84 (-12.94 to -8.75)
SecondaryChange in Sitting Pulse Pressure During the Extension Phase of the Study

Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.

Time frame:
Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Reported as:
Mean · mmHg
Change in Sitting Pulse Pressure During the Extension Phase of the Study
mmHgAmlodipine+Valsartan+HCTZ - Phase 3
Change in Sitting Pulse Pressure During the Extension Phase of the Study-5.62 (-7.74 to -3.50)
SecondaryChange in Sitting Pulse Rate During the Extension Phase of the Study

Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.

Time frame:
Baseline Phase 3 (Week 8) to end of Phase 3 (week 12)
Reported as:
Mean · BPM (beats per minute)
Change in Sitting Pulse Rate During the Extension Phase of the Study
BPM (beats per minute)Amlodipine+Valsartan+HCTZ - Phase 3
Change in Sitting Pulse Rate During the Extension Phase of the Study0.09 (-1.36 to 1.54)
SecondaryPercentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study

Normalized Blood Pressure was defined as a msSBP \< 140 mmHg and/or a msDBP \< 90 mmHg.

Time frame:
Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study
Percentage of participantsAmlodipine+Valsartan+HCTZ - Phase 3
msSBP < 140 mmHg59.3
msDBP < 90 mmHg83.5
SecondaryPercentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study

Blood pressure response was defined as msSBP \< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 3 compared to Baseline in Phase 3 or a msDBP \< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 3 compared to Baseline in Phase 3.

Time frame:
Baseline of Phase 3 (Week 8) to end of Phase 3 (Week 12)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study
Percentage of participantsAmlodipine+Valsartan+HCTZ - Phase 3
msSBP response61.5
msDBP response83.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 - Amlodipine+Olmesartan—1/257 (0.4%)0/257 (0%)
Phase 2 - Amlodipine+Valsartan—0/176 (0%)0/176 (0%)
Phase 3 - Amlodipine+Valsartan+HCTZ—0/91 (0%)0/91 (0%)
Most frequent serious events
Most frequent serious events
EventPhase 1 - Amlodipine+OlmesartanPhase 2 - Amlodipine+ValsartanPhase 3 - Amlodipine+Valsartan+HCTZ
SUDDEN HEARING LOSSEar and labyrinth disorders1/2570/1760/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ
Phase 1 - Amlodipine+olmesartan58.8 ± 12.38
Phase 2 - Amlodipine+valsartan59.8 ± 11.84
Phase 3 - Amlodipine+valsartan+HCTZ60.9 ± 10.98
Sex/Gender, Customized
Sex/Gender, Customized(participants)Amlodipine(AML)+Olmesartan, AML+Valsartan, AML+Valsartan+HCTZ
Phase 1 - Amlodipine+olmesartan - Female112
Phase 1 - Amlodipine+olmesartan - Male145
Phase 2 - Amlodipine+valsartan - Female76
Phase 2 - Amlodipine+valsartan - Male100
Phase 3 - Amlodipine+valsartan+HCTZ - Female32
Phase 3 - Amlodipine+valsartan+HCTZ - Male59
08

Study locations

2 sites
  • Novartis Investigative Site, , Germany
    Schwerin, Germany
  • 30 sites in Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2007
First posted
Aug 31, 2007
Start
Jul 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
May 25, 2011
Last update
Aug 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00523744
Lead sponsor
Novartis
First posted
Aug 31, 2007
Start date
Jul 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
May 25, 2011
Last update
Aug 4, 2020

Study contacts

Novartis Pharmaceuticals
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Valsartan

Start the discussion